INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial. - Université de Lille Accéder directement au contenu
Article Dans Une Revue Inflammatory Bowel Diseases Année : 2022

INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial.

J. Panés
  • Fonction : Auteur
G. Bouma
  • Fonction : Auteur
M. Ferrante
  • Fonction : Auteur
T. Kucharzik
  • Fonction : Auteur
F. de la Portilla de Juan
  • Fonction : Auteur
W. Reinisch
  • Fonction : Auteur
F. Selvaggi
  • Fonction : Auteur
J. Tschmelitsch
  • Fonction : Auteur
N. R. Brett
  • Fonction : Auteur
M. Ladouceur
  • Fonction : Auteur
M. Binek
  • Fonction : Auteur
G. Hantsbarger
  • Fonction : Auteur
S. Campbell-Hill
  • Fonction : Auteur
C. Karki
  • Fonction : Auteur
C. Buskens
  • Fonction : Auteur

Résumé

Background The efficacy of a single administration of darvadstrocel (expanded allogeneic adipose-derived mesenchymal stem cells) for treating complex perianal fistulas in patients with Crohn’s disease was demonstrated in a randomized, double-blind trial (ADMIRE-CD [Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn\'s Disease] trial). The current chart review study (INSPECT [A retrospectIve chart review study evaluatINg the longer-term effectiveneSs of darvadstrocel in PatiEnts who CompleTed ADMIRE-CD]) evaluated the longer-term effectiveness and safety of darvadstrocel. Methods Eligible patients had completed at least 52 weeks in the ADMIRE-CD trial. Data on clinical remission and fistula relapse outcomes were collected retrospectively at 104 and 156 weeks after treatment. Adverse events of special interest (tumorigenicity and ectopic tissue formation) were collected up to 208 weeks after treatment. Results Eighty-nine patients were included (43 darvadstrocel patients, 46 control subjects). At 52, 104, and 156 weeks posttreatment, clinical remission was observed in 29 (67.4%) of 43, 23 (53.5%) of 43, and 23 (53.5%) of 43 darvadstrocel-treated patients, compared with 24 (52.2%) of 46, 20 (43.5%) of 46, and 21 (45.7%) of 46 control subjects, respectively. In patients with clinical remission at week 52, this remission was sustained at 104 and 156 weeks after treatment in 19 (65.5%) of 29 and 16 (55.2%) of 29 darvadstrocel-treated patients and in 17 (70.8%) of 24 and 13 (54.2%) of 24 control subjects, respectively. Time to fistula relapse and incidence of fistula relapse or new fistula occurrence were not significantly different between groups. Tumorigenicity was reported for 1 (2.2%) patient in the control group (malignant epidermoid carcinoma). No ectopic tissue formation was reported. Conclusions Real-world follow-up of patients from the ADMIRE-CD trial indicates that clinical remission of complex perianal fistulas can be sustained in the long term irrespective of whether it is achieved through darvadstrocel administration or maintenance treatment regimens and confirms a favorable long-term safety profile of darvadstrocel.

Dates et versions

hal-04516270 , version 1 (22-03-2024)

Identifiants

Citer

J. Panés, G. Bouma, M. Ferrante, T. Kucharzik, Maria Nachury, et al.. INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial.. Inflammatory Bowel Diseases, 2022, Inflammatory Bowel Diseases, 28, pp.1737-1745. ⟨10.1093/ibd/izab361⟩. ⟨hal-04516270⟩

Collections

RIIP UNIV-LILLE
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More